Risk factors associated with the mucormycosis epidemic during the COVID-19 pandemic.
COVID-19 associated mucormycosis
Mucormycosis
Risk factors
Journal
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
ISSN: 1878-3511
Titre abrégé: Int J Infect Dis
Pays: Canada
ID NLM: 9610933
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
16
06
2021
revised:
13
08
2021
accepted:
15
08
2021
pubmed:
28
8
2021
medline:
8
10
2021
entrez:
27
8
2021
Statut:
ppublish
Résumé
This study was performed to assess the risk factors driving the epidemic of coronavirus disease 2019 (COVID-19)-associated mucormycosis (COVID-Mucor) in India that has accompanied the COVID-19 pandemic, particularly during the second wave. Risk factors were analysed among 164 participants: 132 COVID-Mucor (cases) and 32 non-COVID-Mucor (controls). Data from a prospective cohort study of mucormycosis over a period of 1 year were used. Diabetes mellitus remained a significant risk factor in both groups (97%), while uncontrolled diabetes mellitus (odds ratio (OR) 4.6; P = 0.026) and newly detected diabetes (OR 3.3; P = 0.018) were more common among the cases. Most patients with COVID-Mucor had mild COVID-19. Steroid use, often unwarranted, was highly associated with COVID-Mucor after adjusting for other risk factors (OR 28.4; P = 0.001). Serum ferritin was significantly higher (P = 0.041), while C-reactive protein was not, suggesting that alterations in iron metabolism may predispose to COVID-Mucor. Oxygen was used only in a small minority of patients with COVID-Mucor. The in-hospital mortality in both groups was low. In conclusion, the Indian COVID-Mucor epidemic has likely been driven by a convergence of interlinked risk factors: uncontrolled diabetes mellitus, unwarranted steroid use, and perhaps COVID-19 itself. Appropriate steroid use in patients with severe COVID-19 and screening and optimal control of hyperglycaemia can prevent COVID-Mucor.
Identifiants
pubmed: 34450284
pii: S1201-9712(21)00670-6
doi: 10.1016/j.ijid.2021.08.037
pmc: PMC8383616
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
267-270Informations de copyright
Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare no conflict of interest.
Références
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
Emerg Infect Dis. 2021 Sep;27(9):2349-2359
pubmed: 34087089
Med Mycol. 2006 Jun;44(4):335-42
pubmed: 16772227
Diabetes Metab. 2012 Jun;38(3):193-204
pubmed: 22386924
Clin Microbiol Infect. 2009 Oct;15 Suppl 5:26-32
pubmed: 19754753
Nat Metab. 2021 Jun;3(6):774-785
pubmed: 34035524
J Maxillofac Oral Surg. 2021 Mar 6;:1-8
pubmed: 33716414